Cargando…

Characterising an aromatase inhibitor resistant breast cancer cell line

Detalles Bibliográficos
Autores principales:	Harris, E, Varešlija, D, O'Hara, J, Hill, A, Young, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426028/ http://dx.doi.org/10.1186/1753-6561-6-S4-P3

Ejemplares similares

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Use of aromatase inhibitor in a girl with peripheral precocious puberty
por: Lee, CY, et al.
Publicado: (2013)

Dysregulated metabolism and the regulation of aromatase in breast adipose stromal cells in obesity and cancer
por: Samarajeewa, Nirukshi U, et al.
Publicado: (2012)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018)

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
por: Freedman, OC, et al.
Publicado: (2009)

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

The genomic landscape associated with resistance to aromatase inhibitors in breast cancer
por: Sadasivam, Kirithika, et al.
Publicado: (2023)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Potential use of COX-2–aromatase inhibitor combinations in breast cancer
por: Bundred, N J, et al.
Publicado: (2005)

Characterisation of the tumour suppressor gene ZAC in breast tissue
por: Valleley, EM, et al.
Publicado: (2006)

Characterisation of E12/E47 expression in colorectal cancer
por: Chugha, AS, et al.
Publicado: (2015)

PB.24: Is digital breast tomosynthesis helpful within a symptomatic one-stop breast clinic for characterisation of subtle findings?
por: Bansal, GJ, et al.
Publicado: (2013)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Molecular characterization of breast cell lines: a tool for breast cancer studies
por: Charafe-Jauffret, E, et al.
Publicado: (2005)

Identifying candidate genes for variation in sleep-related quantitative traits
por: Joshi, Shreyas, et al.
Publicado: (2014)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Exome sequencing identifies somatic point mutations associated with acquired endocrine resistance in breast cancer cell lines
por: Ehlers, Natasja S, et al.
Publicado: (2012)

Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
por: Hayashi, Takanori, et al.
Publicado: (2018)

Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer
por: Hoppe, Reiner, et al.
Publicado: (2016)

Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells
por: Augimeri, Giuseppina, et al.
Publicado: (2020)

Inhibitor of apoptosis proteins in breast cancer
por: Foster, FM, et al.
Publicado: (2006)

The effects of aromatase inhibitors on lipids and thrombosis
por: Bundred, N J
Publicado: (2005)

Initial outcome of contrast-enhanced spectral mammography in lesion characterisation in the mammographically dense breast
por: Hussain, Zeiad, et al.
Publicado: (2015)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Aromatase inhibitors in advanced breast cancer: there are efficacy differences
por: Bhatnagar, A S
Publicado: (2005)

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Effects of different carbohydrates and protein recovery mixtures on exogenous and endogenous substrate oxidation during subsequent exercise
por: Warrick, Eva, et al.
Publicado: (2009)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

GLUT expression and 18F-FDG uptake in breast cancer cell lines
por: Abrantes, Ana M, et al.
Publicado: (2010)

Developmental protein HOXC11 cooperates with SRC-1 in breast cancer: an adaptive response to endocrine therapy
por: McIlroy, M, et al.
Publicado: (2010)

Role of p27 in tamoxifen response in breast cancer cell lines
por: Nilsson, S, et al.
Publicado: (2009)

Characterisation of a spumavirus Gag protein
por: Goldstone, David C, et al.
Publicado: (2013)

Characterising the performance of balanced memory networks
por: Metaxas, Alex, et al.
Publicado: (2013)

RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours
por: Cooper, WN, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_lu2r4e6rc6snqp4f8p2lmd6p1j